Clinical Trials Logo
NCT number NCT01905046
Study type Interventional
Source Alliance for Clinical Trials in Oncology
Contact Victoria Seewaldt, MD
Phone (626) 471-7321
Status Recruiting
Phase Phase 3
Start date August 2013

Clinical Trial Summary

The purpose of this research study is to test whether metformin, a drug commonly used to treat diabetes, is able to get rid of atypia (early cell changes that are thought to be a marker of breast cancer risk) in women at increased risk for breast cancer. There will be testing for the presence of atypia in the breast after metformin is given to see if it can get rid of atypia. The study will compare the effects, good and/or bad, of metformin or placebo on atypia to find out which is better.

Note: The standard drug used for the "breast cancer prevention" is tamoxifen. If the patient is eligible to take tamoxifen, he/she must be offered tamoxifen prevention as part of clinical care. Metformin and tamoxifen are not similar and function differently. This study is not investigating the use of tamoxifen. Metformin is not approved for preventing breast cancer, but is currently being tested to determine if it can prevent breast cancer.

Clinical Trial Description

A total of 400 premenopausal women (200 per arm) will be pre-registered, among which 300 patients with atypia (Masood Score 14-17) on random periareolar fine needle aspiration (RPFNA) at baseline are expected to be randomized between Metformin and placebo control arm. It is expected that the accrual rate will be 5 to 10 patients per month and that accrual will be completed about 4 years after study activation. The randomization will be stratified for known BRCA mutation (BRCA1 or BRCA2 mutation vs. no mutation), prior excisional biopsy (atypical epithelial hyperplasia, atypical lobular hyperplasia, flat epithelial hyperplasia vs. DCIS vs. LCIS), and baseline fasting insulin > 2x ULN vs. ≤ 2x ULN.

The primary and secondary objectives are described below.

Primary Objective:

• Test for the presence or absence of cytological atypia in RPFNA bilateral aspirates after 12 and 24 months (24 month is optional for placebo-only group for patients who remain on placebo arm and will not receive metformin) for women receiving metformin versus placebo control. The presence of cytological atypia means any atypia in any RPFNA specimen.

Secondary Objectives:

- Use the Masood Cytology Index Score to test for the presence of cytological atypia or disappearance of cytological atypia in RPFNA bilateral aspirates after 12 months for both arms, and 24 months (24 month is optional for placebo-only group for patients who remain on placebo arm and will not receive metformin, and mandatory for crossover patients) for women receiving metformin 850 mg PO BID (metformin group).

- Compare Masood Cytology Score values at 0 and 12 months in the right and left breasts from the same individual in the metformin and placebo groups.

- Test the reproducibility of reverse phase protein microarray (RPPM) in duplicate RPPM determinations from individual RPFNA specimens.

- Correlate baseline RPPM values with presence of atypia (as measured by Masood Cytology Index Score) at month 12 and month 24 (month 24 optional for placebo-only group; for patients who remain on placebo arm and will not receive metformin) RPFNA.

- Determine the change in percent breast density from prior to the initiation of metformin or placebo treatment through therapy (ie, at 12 and 24 months), and following therapy (ie, 36 and 48 months).

Follow up visits will be performed at 36 and 48 months after the start of treatment.

Study Design

Related Conditions & MeSH terms

See also
Status Clinical Trial Phase
 Recruiting NCT02314156 - Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Phase 2
 Completed NCT01874184 - Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer N/A
 Recruiting NCT01869764 - Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer N/A
 Active, not recruiting NCT02587663 - Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI N/A
 Active, not recruiting NCT00769379 - Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Phase 3
 Recruiting NCT01753908 - Broccoli Sprout Extract in Treating Patients With Breast Cancer N/A
 Terminated NCT02023008 - Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy N/A
 Active, not recruiting NCT01849250 - Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Phase 2
 Terminated NCT01754519 - Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery Phase 2
 Recruiting NCT02352883 - MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ N/A
 Recruiting NCT01819233 - Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy N/A
 Completed NCT01723943 - Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients N/A
 Completed NCT00637481 - A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer Phase 1
 Recruiting NCT02526498 - Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery Phase 2
 Suspended NCT02186470 - Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer N/A
 Recruiting NCT01975363 - Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer N/A
 Recruiting NCT02636582 - Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer Phase 2
 Not yet recruiting NCT02993159 - Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer Phase 2
 Active, not recruiting NCT01219075 - Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer N/A
 Recruiting NCT02694809 - Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery Phase 2